Track cost pressure
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Explore British National Formulary presentations, drill into dispensing trend data, and identify which pharmacies drive the greatest usage of each medicine.
| Presentation | Product | Chemical substance | Chapter | Items dispensed |
|---|---|---|---|---|
|
Octalbin 5% solution for infusion 500ml bottles
0902022A0BGACAN
|
Octalbin | Albumin solution | Nutrition and Blood | No data available |
|
Octanate LV 1,000unit inj vials
0211000I0BSACBG
|
Octanate LV | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octanate LV 500unit inj vials
0211000I0BSADBF
|
Octanate LV | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octim 150micrograms/dose nasal spray
0605020E0BIAAAS
|
Octim | Desmopressin acetate | Endocrine System | No data available |
|
Octim 15micrograms/1ml solution for injection ampoules
0605020E0BIABBK
|
Octim | Desmopressin acetate | Endocrine System | No data available |
|
Octocog alfa 1,000unit inj vials
0211000I0AAAHAH
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octocog alfa 1,500unit inf vials
0211000I0AAALAL
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octocog alfa 2,000unit inj vials
0211000I0AAAIAI
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octocog alfa 250unit inj vials
0211000I0AAAFAF
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octocog alfa 3,000unit inf vials
0211000I0AAAPAP
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octocog alfa 500unit inj vials
0211000I0AAAGAG
|
Factor VIII Fraction | Dried factor VIII fraction | Cardiovascular System | No data available |
|
Octreotide 50micrograms/1ml solution for injection vials
0803043N0AAAKAK
|
Octreotide acetate | Octreotide acetate | Malignant Disease and Immunosuppression | No data available |
|
Ocufresh Comfort Singles Carmellose 0.5% eye drops 0.4ml unit dose preservative free
21300000994
|
Ocufresh Comfort Singles Carmellose 0.5% eye drops 0.4ml unit dose preservative free | Eye Products | Appliances | No data available |
|
Oculotect 5% eye drops 0.4ml unit dose
1108010T0BBAAAA
|
Oculotect | Povidone K 25 | Eye | No data available |
|
Ocutrop 1% eye drops
1105000B0BEAAAE
|
Ocutrop | Atropine sulfate | Eye | No data available |
|
Odour Free Lloyds cream
1003020I0BDAAAA
|
Odour Free Lloyds | Diethylamine salicylate | Musculoskeletal and Joint Diseases | No data available |
|
Odrik 1mg capsules
0205051U0BCABAB
|
Odrik | Trandolapril | Cardiovascular System | No data available |
|
Odrik 2mg capsules
0205051U0BCACAC
|
Odrik | Trandolapril | Cardiovascular System | No data available |
|
Odrik 500microgram capsules
0205051U0BCAAAA
|
Odrik | Trandolapril | Cardiovascular System | No data available |
|
Oestraclin 0.06% gel
0604011G0BYAAAU
|
Oestraclin | Estradiol | Endocrine System | No data available |
|
Ofatumumab 20mg/0.4ml inj pre-filled disposable devices
0802040BDAAAAAA
|
Ofatumumab | Ofatumumab | Malignant Disease and Immunosuppression | No data available |
|
Ofcram PR 200mg capsules
0209000L0BHAAAM
|
Ofcram PR | Dipyridamole | Cardiovascular System | No data available |
|
Ofev 100mg capsules
0801050BTBCAAAA
|
Ofev | Nintedanib | Malignant Disease and Immunosuppression | No data available |
|
Ofloxacin 0.3% ear drops
1201010ABAAAAAA
|
Ofloxacin (Ear) | Ofloxacin | Ear, Nose and Oropharynx | No data available |
|
Ofloxacin 100mg/5ml oral liquid
0501120P0AAADAD
|
Ofloxacin (Systemic) | Ofloxacin | Infections | No data available |
Link medicine usage to pharmacy and prescriber behaviour to find optimisation opportunities.
Identify presentations with rising spend and create intervention plans focused on switching opportunities or formulary alignment.
Cross-reference high-volume medicines with local health priorities and prescriber activity to target support programs.